Genentech, Inc.

US/Swiss biotech GlycoEra AG announced a $130m series B financing on 27 May that it says will enable it to advance its first protein-degradation drug candidate through Phase II proof of concept as pre

The results from Genentech ‘s STARGLO study of lymphoma drug Columvi (glofitamab-gxbm) are not generalizable to the US due to the small number of enrolled American patients and adverse results across

The European Medicines Agency is this week deciding whether to recommend pan-EU marketing authorization for a number of new medicines, including obecabtagene autoleucel (obe-cel), Autolus Therapeutics

Future approval standards for drugs treating low-grade, intermediate-risk, non-muscle invasive bladder cancer (LG-IR-NMIBC) will be at issue during a US Food and Drug Administration advisory committee